ContraFect Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ContraFect Corporation, formerly a clinical-stage biotechnology enterprise, specialized in the identification and advancement of therapeutic protein and antibody products designed to combat severe, drug-resistant infectious diseases. The company's primary focus centered on direct lytic agents, including lysins and amurin peptides, to offer novel treatment modalities. Its lead candidate, exebacase, a lysin, had progressed into Phase 3 clinical trials for addressing *Staphylococcus aureus* bacteremia, including instances of methicillin-resistant *Staphylococcus aureus* (MRSA). Further efforts included developing CF-296, an engineered lysin, aimed at invasive *Staphylococcus aureus* infections, such as those related to biofilms in prosthetic joints. Additionally, ContraFect was advancing CF-370, an investigational anti-bacterial lysin, through Phase 1 clinical studies for treating Gram-negative pathogens like *Pseudomonas aeruginosa*, associated with conditions such as hospital-acquired and ventilator-associated bacterial pneumonia. However, facing liquidity challenges, the company initiated Chapter 7 bankruptcy proceedings in December 2023. Subsequently, in March 2024, substantially all of ContraFect's intellectual property assets were acquired by Aurobac Therapeutics SAS through a Section 363 sale process. ContraFect Corporation was established in 2008 and previously maintained its headquarters in Yonkers, New York.
Company News
Why Is ContraFect (CFRX) Stock Up 23% Today?
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
Discover the Top Penny Stock Technical Indicators By Effectiveness
Why Is ContraFect (CFRX) Stock Down 14% Today?
The Future of Buying Penny Stocks: Trends for 2023
Penny Stock Investing for Passive Income: Opportunities and Risks
3 Short Squeeze Penny Stocks To Watch After CFRX Stock Explodes
Why Is ContraFect (CFRX) Stock Up 20% Today?
Why Is ContraFect (CFRX) Stock Down 23% Today?
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
Zephyr AI Announces Additions to the Board of Directors
Why Is ContraFect (CFRX) Stock Down 80% Today?
Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022